## SEC Form 4

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287				
Estimated average burden					
hours per response	.: 0.5				

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			of Section So(n) of the investment Company Act of 1940		
1. Name and Address of Reporting Person* <u>Medpace Investors, LLC</u>			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Medpace Holdings, Inc.</u> [ MEDP ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner	
	-				
(Last) (First) (Middle) C/O MEDPACE HOLDINGS, INC. 5375 MEDPACE WAY			3. Date of Earliest Transaction (Month/Day/Year) 12/30/2021	Officer (give title Other (specify below)	
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicab Line)	
(Street)				X Form filed by One Reporting Person	
CINCINNATI	OH	45227		Form filed by More than One Reporting Person	
(City)	(State)	(Zip)			

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	12/30/2021		<b>S</b> <sup>(1)</sup>		17,376 <sup>(1)</sup>	D	\$220.34(2)	5,519,170	D	
Common Stock	12/31/2021		<b>S</b> <sup>(1)</sup>		13,069(1)	D	\$219.14 <sup>(3)</sup>	5,506,101	D	
Common Stock	01/03/2022		<b>S</b> <sup>(1)</sup>		19,744 <sup>(1)</sup>	D	\$212.7 <sup>(4)</sup>	5,486,357	D	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(0.9.) P	110, 01		vante		options, c		10 30	oundes	,		
. Title of verivative iecurity instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

#### Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

2. The reported price is a weighted average price. These series were sold in multiple transactions ranging from \$218.835 to \$222.14. The Reporting Person undertakes to provide full pricing information

to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. 3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$217.48 to \$220.44. The Reporting Person undertakes to provide full pricing information to

the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. 4. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$210.00 to \$217.36. The Reporting Person undertakes to provide full pricing information to the Use of the Use of the Commission of Commission Commission Commission and the Use of the Use of the Use of the Use of the Commission of Commission and the Use of the Use of

the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

<u>/s/ Stephen P. Ewald,</u>	
Authorized Signatory for	01/04/2022
Medpace Investors, LLC	

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).